Modulation of Gene Expression in Human Breast Cancer MCF7 and Prostate Cancer PC3 Cells by the Human Copper-Binding Peptide GHK-Cu.
Abstract
(ISSN 2577-5790)
OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Publication Speed (median values for papers published in 2023): Submission to First Decision: 5.1 weeks; Submission to Acceptance: 17.0 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)
Special Issue
Cancer Genetics and Epigenetics Alterations
Submission Deadline: October 31, 2020 (Closed) Submit Now
Guest Editor
Lunawati L Bennett, MS, PhD, PharmD, FACN
Professor of Pharmaceutical Sciences, Union University College of Pharmacy, Jackson, Tennessee, USA
Research Interests: role of antioxidants and nutraceuticals in cancer, pharmacogenomics, treatment of rare diseases, cancer genetics, leukemia, breast cancer, colorectal cancer, lung cancer, and brain cancer
About This Topic
Upcoming insight into understanding cancer genetics and epigenetic aberration of different type of cancers. Cancer is heterogeneous disease arise from defects in the structures of cells, aberration of genes, or alteration in key cellular pathways that regulate proliferation, differentiation, and apoptosis of normal cells. The mutations in cancer are usually due to gain-of-function of proto-oncogenes becomes oncogenes and/or loss function of tumor suppressor genes. Epigenetic mechanism also plays critical role in altering the patterns and levels of protein expression of certain genes, chromatin modifying protein, DNA methylation and patterns of gene expression in cancer cells. Although diverse mutations and gene expression changes have been implicated in cancer pathogenesis, the defects appear to limited number of gene alterations such as RAS, EGFR, PTEN, p53, Akt, PTEN and others; however, the accumulated multiple genetics and epigenetics defects play fundamental role in cancer initiation and progression.
This issue primary aims is to understand how persons genetics, chemical carcinogenesis, environment, gut microbes, dietary factors, and epigenetic alterations play important role in cancer initiation and progression.
Keywords: genetic defects; cancer alter signaling pathways; genomic integrity, oncogene mutations; tumor suppressor; proto oncogene; epigenetic alterations; chromatin regulator; histone hyper-methylation; histone hypo-methylation
Planned Paper
Title: HDAC as potential therapeutic targets in glioblastoma therapy
Author: Luca Colucci-D’Amato
Title: Genetic variants of targetable cancer-related genes in vestibular schwannomas
Author: Cesar Wong
Abstract: A vestibular schwannoma (VS) is a benign primary intracranial tumor of the myelin-forming cells of the vestibulocochlear nerve (8th cranial nerve). A type of schwannoma, this tumor arises from the Schwann cells responsible for the myelin sheath that helps keep peripheral nerves insulated. The primary symptoms of vestibular schwannoma are unexplained progressive unilateral hearing loss and tinnitus and vestibular (disequilibrium) symptoms. Treatment of the condition is by surgery or radiation and often results in substantial or complete hearing loss in the affected ear. Observation (non-treatment) over time also usually results in hearing loss in the affected ear.
Manuscript Submission Information
Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (genetics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.
Welcome your submission!
Publication
Modulation of Gene Expression in Human Breast Cancer MCF7 and Prostate Cancer PC3 Cells by the Human Copper-Binding Peptide GHK-Cu.by
Loren Pickart
and
Anna Margolina
Abstract Breast cancer is the most commonly diagnosed cancer in women, while prostate cancer is the most common cancer affecting men. Despite significant advances in diagnostics and treatment, these cancers have a high risk of metastases and greatly reduce quality of life. Recently, it has been established that multiple epigenetic alterations in gene [...] |
EBF1 Exhibits Crosstalk Regulation with ERα and ERβ in Some Hormone-Based CancersAbstract Estrogen-based cancers affect a substantial portion of the female population in the United States. While multiple studies have examined the effect of estrogen receptor alpha (ERα/ESR1) in cancer, the effects of ERβ/ESR2 are not as well understood in tumor tissues. Furthermore, there are few studies examining the role of specific binding [...] |
Genetic Variants of Targetable Cancer-related Genes in Vestibular Schwannomasby
Alvin Ho Kwan Cheung
,
Nancy Bo-Yin Tsui
,
William Chi Shing Cho
,
Xiao-Meng Pei
,
Yin Kwan Evelyn Wong
,
Hin-Fung Andy Tsang
,
Gilberto Ka-Kit Leung
and
Sze-Chuen Cesar Wong
Abstract Background: Vestibular schwannoma is an intracranial tumor which can lead to devastating neurological deficit and is prone to recurrence after surgery. Patients with inherited neurofibromatosis type 2 (NF2) syndrome are particularly susceptible to bilateral and aggressive schwannomas. However, the genome of vestibular schwannomas is not well [...] |
MSIGNET: A Bayesian Approach for Disease-associated Gene Network Identificationby
Xi Chen
and
Jianhua Xuan
Abstract The analysis of gene networks and signalling pathways plays a key role in understanding gene functions, i.e., their effects on the development of a particular disease. Yet, for many heterogeneous diseases, the number of known disease-associated genes is limited. Identifying disease-associated genes is still an open challenge. To [...] |
Nutrition, Cancer Genetics and EpigeneticsAbstract A strong association has been established between nutrition and disease risk confirmed by epidemiological data and meta-analysis. In the context of cancer, unhealthy diets have been demonstrated to increase the risk of disease. On the other hand, major dietary interventions and lifestyle changes have provided therapeutic efficacy in cancer [...] |
Family History, Genetic, and Other Cause-Related Beliefs among Breast Cancer Survivorsby
Leanna J. Standish
,
Erin Sweet
,
Shelly Hager
,
Marcia Gaul
,
Kelsey Afdem
and
M. Robyn Andersen
Abstract Patients’ lay theories about the cause of their cancer may influence patient behavior and adjustment, they have also been found to differ substantially from scientific evidence of cancer risk factors. This report describes beliefs about genetic causes of breast cancer, among 522 recently diagnosed breast cancer survivors participating in [...] |
2023 | ||
CiteScore | SJR | SNIP |
0.4 | 0.160 | 0.093 |
TOP